John R. MacDonald

2.6k total citations
92 papers, 2.2k citations indexed

About

John R. MacDonald is a scholar working on Molecular Biology, Oncology and Electrical and Electronic Engineering. According to data from OpenAlex, John R. MacDonald has authored 92 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 27 papers in Oncology and 18 papers in Electrical and Electronic Engineering. Recurrent topics in John R. MacDonald's work include Cancer Treatment and Pharmacology (16 papers), Cancer therapeutics and mechanisms (13 papers) and Advanced Fiber Laser Technologies (12 papers). John R. MacDonald is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Cancer therapeutics and mechanisms (13 papers) and Advanced Fiber Laser Technologies (12 papers). John R. MacDonald collaborates with scholars based in United States, United Kingdom and France. John R. MacDonald's co-authors include A. K. Kar, Qin-Wei Yin, David Prevette, Frank M. Collins, Ronald W. Oppenheim, Debaditya Choudhury, Jan M. Woynarowski, Stephen J. Beecher, Stephen J. Waters and Daniel D. Von Hoff and has published in prestigious journals such as Science, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

John R. MacDonald

88 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John R. MacDonald United States 26 838 460 332 308 266 92 2.2k
Tatiana K. Rostovtseva United States 37 3.5k 4.2× 96 0.2× 212 0.6× 114 0.4× 727 2.7× 88 4.4k
Victor G. Zgoda Russia 25 1.5k 1.8× 158 0.3× 52 0.2× 62 0.2× 74 0.3× 209 2.3k
Timothy A. Lewis United States 29 2.0k 2.3× 502 1.1× 53 0.2× 129 0.4× 157 0.6× 78 3.8k
J. Henningsen Denmark 19 948 1.1× 160 0.3× 225 0.7× 206 0.7× 48 0.2× 40 1.7k
Elisa Ferrando‐May Germany 27 1.5k 1.8× 423 0.9× 89 0.3× 37 0.1× 145 0.5× 50 2.1k
Arthur T. Kopylov Russia 23 1.1k 1.3× 112 0.2× 77 0.2× 75 0.2× 90 0.3× 158 1.9k
Thomas A. Shaler United States 24 2.8k 3.3× 243 0.5× 21 0.1× 75 0.2× 405 1.5× 39 4.0k
James T. Murray United States 29 1.4k 1.7× 167 0.4× 715 2.2× 617 2.0× 73 0.3× 80 2.9k
Christopher J. Turner United States 26 1.2k 1.4× 374 0.8× 27 0.1× 42 0.1× 453 1.7× 68 2.3k
Kenneth T. Wheeler United States 39 2.5k 2.9× 534 1.2× 34 0.1× 48 0.2× 584 2.2× 131 4.6k

Countries citing papers authored by John R. MacDonald

Since Specialization
Citations

This map shows the geographic impact of John R. MacDonald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. MacDonald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. MacDonald more than expected).

Fields of papers citing papers by John R. MacDonald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. MacDonald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. MacDonald. The network helps show where John R. MacDonald may publish in the future.

Co-authorship network of co-authors of John R. MacDonald

This figure shows the co-authorship network connecting the top 25 collaborators of John R. MacDonald. A scholar is included among the top collaborators of John R. MacDonald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. MacDonald. John R. MacDonald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
MacDonald, John R., Stephen J. Beecher, Patrick A. Berry, et al.. (2013). Efficient mid-infrared Cr:ZnSe channel waveguide laser operating at 2486 nm. Optics Letters. 38(13). 2194–2194. 42 indexed citations
2.
Ródenas, Airán, Antonio Benayas, John R. MacDonald, et al.. (2011). Direct laser writing of near-IR step-index buried channel waveguides in rare earth doped YAG. Optics Letters. 36(17). 3395–3395. 32 indexed citations
3.
MacDonald, John R., Robert R. Thomson, Stephen J. Beecher, et al.. (2010). Ultrafast laser inscription of near-infrared waveguides in polycrystalline ZnSe. Optics Letters. 35(23). 4036–4036. 53 indexed citations
4.
Dings, Ruud P.M., Yan Zhang, Robert J. Griffin, et al.. (2008). Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters. 265(2). 270–280. 42 indexed citations
5.
Hilgers, Werner, Sandrine Faivre, Jérôme Alexandre, et al.. (2006). A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Investigational New Drugs. 24(4). 311–319. 13 indexed citations
6.
Senzer, Neil, et al.. (2005). Irofulven Demonstrates Clinical Activity Against Metastatic Hormone-Refractory Prostate Cancer in a Phase 2 Single-Agent Trial. American Journal of Clinical Oncology. 28(1). 36–42. 27 indexed citations
7.
MacDonald, John R.. (2004). Treatment of localized gastric cancer. Seminars in Oncology. 31(4). 566–573. 42 indexed citations
8.
Woynarowski, Jan M., Barbara Woynarowska, Alex V. Trevino, et al.. (2004). Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells. Cancer Biology & Therapy. 3(11). 1137–1142. 28 indexed citations
9.
MacDonald, John R., et al.. (2003). The law of freedom of information. Oxford University Press eBooks. 21 indexed citations
10.
MacDonald, John R.. (2003). Adjuvant therapy for gastric cancer. Seminars in Oncology. 30(4 Suppl 11). 19–25. 12 indexed citations
11.
12.
Thomas, James, Rhoda Arzoomanian, Dona Alberti, et al.. (2001). Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemotherapy and Pharmacology. 48(6). 467–472. 16 indexed citations
13.
MacDonald, John R.. (2001). Adjuvant therapy of colon cancer. Seminars in Oncology. 28(1). 30–40. 74 indexed citations
14.
Hammond, L. A., Susan G. Hilsenbeck, Sabine Eckhardt, et al.. (2000). Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. European Journal of Cancer. 36(18). 2430–2436. 25 indexed citations
15.
Hidalgo, Manuel, Elżbieta Izbicka, S. Gail Eckhardt, et al.. (1999). Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anti-Cancer Drugs. 10(9). 837–844. 20 indexed citations
16.
Herzig, Maryanne C., et al.. (1999). Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochemical Pharmacology. 58(2). 217–225. 47 indexed citations
17.
Woynarowski, Jan M., Cheryl Napier, Steven K. Koester, et al.. (1997). Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochemical Pharmacology. 54(11). 1181–1193. 90 indexed citations
18.
Vernetti, Lawrence A., et al.. (1996). Differential toxicity of an inhibitor of mitochondrial respiration in canine hepatocytes and adrenocortical cell cultures. Toxicology in Vitro. 10(1). 51–57. 5 indexed citations
19.
MacDonald, John R., et al.. (1993). Extravasation injury potential of CI-980 a novel synthetic mitotic inhibitor. Cancer Chemotherapy and Pharmacology. 32(5). 365–367. 3 indexed citations
20.
Vernetti, Lawrence A., et al.. (1993). ATP Depletion Is Associated with Cytotoxicity of a Novel Lipid Regulator in Guinea Pig Adrenocortical Cells. Toxicology and Applied Pharmacology. 118(1). 30–38. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatiana K. Rostovtseva Breakdown of academic impact, for papers by Victor G. Zgoda Breakdown of academic impact, for papers by Timothy A. Lewis Breakdown of academic impact, for papers by J. Henningsen Breakdown of academic impact, for papers by Elisa Ferrando‐May Breakdown of academic impact, for papers by Arthur T. Kopylov Breakdown of academic impact, for papers by Thomas A. Shaler Breakdown of academic impact, for papers by James T. Murray Breakdown of academic impact, for papers by Christopher J. Turner Breakdown of academic impact, for papers by Kenneth T. Wheeler
Rankless by CCL
2026